Biotechnology News and Research

RSS

Children born by Caesarean section more vulnerable to allergies

Children who came into the world by Caesarean section are more often affected by allergies than those born in the natural way. The reason for this may be that they have a less diverse gut microbiota, according to a study by universities in Sweden and Scotland.

9 Aug 2013

CfPIE announces two new training courses for life science professionals

The Center for Professional Innovation and Education has announced two new EU regulations training courses for life science professionals. The new courses – to be presented in early December at the Berlin Hilton in Berlin, Germany, expands upon the thirty other CfPIE courses presented in Europe each year.

9 Aug 2013

FitBionic completes $2.2M funding round with KMG Capital Partners, CID4 and High Country Venture

FitBionic has completed a $2.2 million funding round with a team led by KMG Capital Partners, with High Country Venture and the Colorado Institute for Drug, Device and Diagnostic Development. The investment was developed in support of the global launch of FitBionic's currently available first product, the FitBionic Foot, and as a bridge to the company's Series A financing, which is expected in 2014.

8 Aug 2013

AmpliPhi releases data on phage therapy for treatment of lung infections in Cystic Fibrosis patients

AmpliPhi BioSciences Corp. (OTC: APHB) ("AmpliPhi"), the leader in the development of bacteriophage-based antibacterial therapies to treat drug resistant bacterial infections, yesterday presented data relating to the use of bacteriophages in the treatment of Pseudomonas aeruginosa (P. aeruginosa) at the 20th Biennial Evergreen International Phage Meeting held in Olympia, Washington, USA. P. aeruginosa is the major cause of lung infections in cystic fibrosis (CF) patients.

8 Aug 2013

Scientist receives grant to commercialize technology developed for repairing skin injuries

The Chemical Alliance Zone's Chemicals and Materials Commercialization Fund has awarded $20,000 to a Marshall University scientist to help bring to market a technology he has developed for repairing skin injuries.

8 Aug 2013

Ensemble Therapeutics initiates research and development collaboration with Novartis

Ensemble Therapeutics, a biotechnology company developing Ensemblins, a novel class of small molecule therapeutics with the power of biologics, today announced the initiation of a two-part research and development collaboration with Novartis.

6 Aug 2013

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

A team of scientists, led by Napoleone Ferrara, MD, has shown for the first time that a signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy.

6 Aug 2013

Bayer Collaboration Could Net $540M+ For Compugen

...

6 Aug 2013

Life Tech, Raintree Launch Oncology Testing, Patient Data Initiatives

...

6 Aug 2013

New England Biolabs Gains Access To Advanced NGS Library Prep Method

...

From New England Biolabs 6 Aug 2013

Affymetrix introduces new OncoScan FFPE Assay Kit

Affymetrix, Inc. announced the launch of the new OncoScan™ FFPE Assay Kit, a whole-genome copy number assay for highly degraded FFPE solid tumor samples, at the Cancer Cytogenomics Microarray Consortium conference being held in Chicago this week.

5 Aug 2013

New bioinspired coating makes ordinary glass tough, self-cleaning and incredibly slippery

A new transparent, bioinspired coating makes ordinary glass tough, self-cleaning and incredibly slippery, a team from the Wyss Institute for Biologically Inspired Engineering at Harvard University and Harvard School of Engineering and Applied Sciences (SEAS) reported online in the July 31 edition of Nature Communications.

3 Aug 2013

New survey commissioned by PhRMA identifies America's top health priorities

A new survey commissioned by the Pharmaceutical Research and Manufacturers of America shows 86 percent of Americans believe developing cures for more forms of cancer should be one of the top national health priorities, followed by developing effective treatments for heart disease (78 percent) and more intensive medical care for seniors (76 percent).

2 Aug 2013

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload antibody-drug conjugate technology, today reported financial results for the three-month period and fiscal year ended June 30, 2013. ImmunoGen also provided guidance for its 2014 fiscal year and an update on the Company.

2 Aug 2013

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its Targeted Antibody Payload (TAP) ADC technology, today announced that the Company's x (IND) application has been accepted by the US FDA and is now active.

2 Aug 2013

Research aims to provide physicians a more targeted approach to treating ER+ breast cancer

The most commonly diagnosed form of breast cancer, termed estrogen receptor positive or ER+, accounts for the largest percentage of breast cancer deaths each year. Research by scientists at the HudsonAlpha Institute for Biotechnology and the University of Alabama at Birmingham Comprehensive Cancer Center aims to provide physicians a more targeted approach to treating ER+ breast cancer.

2 Aug 2013

Researchers develop aflocculating agent to separate and remove textile dyes from the water

The European fashion industry is a huge consumer of fresh water. Estimates point to 600 million cubic meter of fresh water being consumed yearly in Europe by the textile and clothing industry; not a negligible amount.

1 Aug 2013

SASB releases first set of provisional standards for industries in Health Care sector

The Sustainability Accounting Standards Board, a 501c3 non-profit organization that provides sustainability accounting standards for use by publicly listed corporations in the U.S., today released its first set of provisional standards for industries in the Health Care sector.

31 Jul 2013

Baxter, JW Holdings sign distribution, license agreement for omega 3 parenteral nutrition products

Baxter International Inc. and JW Holdings today announced that they have entered into an exclusive distribution and license agreement for parenteral nutritional products containing a novel formulation of omega 3 lipids.

From Baxter International Inc. 31 Jul 2013

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

AstraZeneca and FibroGen today announced that they have entered into a strategic collaboration to develop and commercialize FG-4592, a first-in-class oral compound in late stage development for the treatment of anemia associated with chronic kidney disease and end-stage renal disease.

31 Jul 2013

Biotechnology News and Research

Children born by Caesarean section more vulnerable to allergies

CfPIE announces two new training courses for life science professionals

FitBionic completes $2.2M funding round with KMG Capital Partners, CID4 and High Country Venture

AmpliPhi releases data on phage therapy for treatment of lung infections in Cystic Fibrosis patients

Scientist receives grant to commercialize technology developed for repairing skin injuries

Ensemble Therapeutics initiates research and development collaboration with Novartis

Signaling protein involved in inflammation also promotes tumor resistance to anti-angiogenic therapy

Bayer Collaboration Could Net $540M+ For Compugen

Life Tech, Raintree Launch Oncology Testing, Patient Data Initiatives

New England Biolabs Gains Access To Advanced NGS Library Prep Method

Affymetrix introduces new OncoScan FFPE Assay Kit

New bioinspired coating makes ordinary glass tough, self-cleaning and incredibly slippery

New survey commissioned by PhRMA identifies America's top health priorities

ImmunoGen reports net loss of $21.9 million in Q4 2013

ImmunoGen announces FDA approval of IMGN289 Investigational New Drug

Research aims to provide physicians a more targeted approach to treating ER+ breast cancer

Researchers develop aflocculating agent to separate and remove textile dyes from the water

SASB releases first set of provisional standards for industries in Health Care sector

Baxter, JW Holdings sign distribution, license agreement for omega 3 parenteral nutrition products

AstraZeneca, FibroGen partner to develop, commercialize anemia drug candidate FG-4592

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News